<DOC>
	<DOCNO>NCT02444572</DOCNO>
	<brief_summary>Comparison thromboembolic event Enoxa® Lovenox® patient undergo digestive cancer subject thromboprophylaxis .</brief_summary>
	<brief_title>Comparison Thromboembolic Events Between Enoxa® Lovenox® Patients Undergoing Digestive Cancer</brief_title>
	<detailed_description>Comparative study two arm versus ENOXA® LOVENOX® , randomize , prospective , single-center , rater-blinded whose main objective compare incidence thromboembolic event ( symptomatic asymptomatic ) two arm study , patient undergo digestive cancer receive thromboprophylaxis base SODIUM enoxaparin .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>Male female 18 year Digestive Cancer prove whatever nature , site stage Surgical indication emergency program , whatever nature Preventive administration enoxaparin sodium Patients participate another study Impregnation prior Unfractionated heparin ( UFH ) last 30 day Renal impairment creatinine clearance &lt; 30 ml / min Known history peripheral venous thrombosis / deep occur previous 3 month study entry Pregnant breastfeed woman woman childbearing potential use medically accept contraceptive method Taking anticoagulant last three month Patients know haemostatic disorder No one wish participate study , ability understand objective</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>